Evidence on quality-adjusted survival between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) in patients with metastatic breast cancer (MBC) is limited. Using a quality-adjusted time without symptoms or toxicity approach, quality-adjusted survival was evaluated in MBC patients receiving nab-P or Pac in a phase III registration trial. Patients receiving nab-P as second-line or greater therapy had a statistically significant, clinically important improvement in quality-adjusted survival versus those receiving Pac. Background: In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. Patients and Methods: Quality-adjusted overall survival was estimated using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Overall survival was partitioned into time without progression/Grade ! 3 adverse events (AEs) toxicity (TWiST), time with Grade ! 3 AE toxicity (TOX), and time after relapse (REL). Q-TWiST was calculated by multiplying mean time in each health state by its assigned utility (base-case utility values: time without symptoms of disease progression or toxicity of Grade ! 3 adverse events [TWiST] ¼ 1.0, TOX ¼ 0.5, and REL ¼ 0.5). In threshold analyses, TOX and REL varied from 0.0 to 1.0 whereas TWiST was maintained at 1.0. Comparisons were made for the intent-to-treat population and the subset of patients initiating the study drugs as second or subsequent lines (2Lþ) of chemotherapy (per approved nab-P indication; 2Lþ subpopulation). A ! 15% relative Q-TWiST gain (vs. mean Pac overall survival) was considered clearly clinically important. Results: In the intent-to-treat population, nab-P (n ¼ 229) versus Pac (n ¼ 225) resulted in nonsignificant gains of 1.4 months of mean Q-TWiST (11.6 vs. 10.2 months; 95% confidence interval [CI], À0.03 to 2.8). In the 2Lþ subpopulation, nab-P (n ¼ 132) versus Pac (n ¼ 136) resulted in a statistically significant gain of 2.2 months of mean Q-TWiST (10.5 vs. 8.4 months; 95% CI, 0.6-3.8), with a 17.1% relative Q-TWiST gain (threshold analysis range, 14.0%-19.5%, both figures significant). Conclusion: In its approved indication for metastatic breast cancer, nab-P showed a statistically significant and clearly clinically important improvement in quality-adjusted survival time versus Pac in the 2Lþ subpopulation.
Introduction
Breast cancer is the most common cancer and the second leading cause of cancer death in women worldwide. 1, 2 It was estimated that in 2017, 252,710 new cases of female breast cancer would be diagnosed and 40,610 women would die of this disease in the United States. 3, 4 Furthermore, in approximately 20% to 30% of women with early stage breast cancer, the cancer eventually progresses to a metastatic stage, 5 which has a 5-year survival rate of approximately 22%.
Treatment of metastatic breast cancer (MBC) is palliative, with the goals of prolonging survival, controlling symptoms, and improving quality of life (QOL). 7 Thus, treatment selection should include toxicity as a key factor. nab-paclitaxel (nab-P), an albuminbound form of paclitaxel, was designed to improve the therapeutic index of standard paclitaxel (Pac), which is associated with a higher incidence of toxicities, such as hypersensitivity reactions, attributed to the use of solvents. Because it is solvent-free, nab-P reduces the risk of solvent-related adverse reactions and allows shorter infusion times compared with Pac. 8 Preclinical studies have further shown that nab-P has a distinct pharmacokinetic profile compared with Pac, resulting in a faster and greater tissue distribution, shorter duration of systemic exposure, and more efficient and selective tumor accumulation of paclitaxel (33% higher tumor uptake vs. Pac). 9, 10 Clinical studies have also shown that nab-P (vs. Pac)
improved clinical outcomes among patients with MBC. 11, 12 On the basis of these trials, nab-P monotherapy has been approved by the European Medicines Agency and the United States Food and Drug Administration for the treatment of MBC in adult patients in whom first-line treatment for metastatic disease has failed and for whom standard anthracycline-containing therapy is not indicated. 13, 14 However, evidence is limited on quality-adjusted survival for patients who receive nab-P, and no studies have compared qualityadjusted survival between nab-P and Pac in patients with MBC. In this analysis we used data from the phase III registration trial of nab-P versus Pac in MBC to examine the quality-adjusted survival benefits via a quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) approach among the intent-to-treat (ITT) population as well as the subpopulation of patients who initiated the study drugs as second or subsequent lines of chemotherapy (the setting for which nab-P is approved in MBC; hereafter, the 2Lþ subpopulation). The Q-TWiST approach combines quantity and QOL into a single measure by partitioning survival time into a series of health states, and fits cancer studies particularly well because it reflects the outcomes of treatment choices by considering quantity (survival time) as well as QOL (that can be impaired by treatment toxicity). 15, 16 Patients and Methods
Data Source
An open-label, randomized, international, multicenter, phase III study was designed to compare overall response rate, time to progression, and overall survival (OS) between nab-P 260 mg/m 2 intravenously without premedication and Pac 175 mg/m 2 intravenously with premedication every 3 weeks. 11 Patients with MBC were randomized in a 1:1 ratio to receive either nab-P or Pac. Key patient eligibility criteria included nonpregnant women who were not lactating, aged 18 years or older, with a life expectancy of > 12 weeks, Eastern Cooperative Oncology Group (ECOG) performance status of 2, and adequate hematologic, hepatic, and renal function. Patients who had received docetaxel or Pac for metastatic carcinoma before the trial and had relapsed with metastatic disease within 1 year of adjuvant docetaxel or Pac treatment were excluded from the study. 5 
Study Participants
The primary analyses were on the basis of the ITT population (nab-P [n ¼ 229] vs. Pac [n ¼ 225]) and the 2Lþ subpopulation
Other exploratory subgroups included patients with ! 3 metastatic lesions at baseline, patients with visceral metastases (liver, lung, and abdominal) as the dominant metastatic lesion site, and patients with time from initial diagnosis to relapse of < 2 years at baseline.
Study Measures
The Q-TWiST Approach. The Q-TWiST approach was applied in 2 steps in the present study. First, OS time was partitioned into 3 mutually exclusive health states ( Figure 1 ): (1) time without symptoms of disease progression or toxicity (TWiST) of Grade ! 3 adverse events (AEs; white shaded area in Figure 1) ; (2) time with toxicity of Grade ! 3 AEs before disease progression (TOX; dark gray shaded area in Figure 1) ; and (3) postprogression survival time (REL; light gray shaded area in Figure 1 ). The AEs were categorized on the basis of the National Cancer Institute Common Toxicity Criteria (version 2.0). In addition, if a Grade ! 3 AE was recorded as an ongoing event, we used the period from AE onset until disease progression as a surrogate measure of duration. This strategy was conservative and was designed to capture all time spent with toxicity before progression. The time period of each health state is defined in Figure 1 . Q-TWiST Analysis of nab-P Versus Pac in MBC Second, we assigned the utility value of TWiST (U TWiST ) to be 1.0, representing a perfect health state. U TOX and U REL represent the utilities of TOX and REL, respectively, and were assumed to be 0.5 within the base case. These are commonly used utilities for basecase scenario in Q-TWiST literature. 17, 18 Then Q-TWiST was calculated as the sum of the mean durations of the 3 health states mentioned previously, weighted by their level of utility (Equation 1). The 95% confidence intervals (CIs) of survival time in each health state and Q-TWiST were calculated using a nonparametric bootstrap method:
The relative gain in Q-TWiST between nab-P and Pac was defined as the difference in mean Q-TWiST divided by mean OS in the Pac group. A ! 15% relative Q-TWiST gain (vs. mean Pac OS) was considered clearly clinically important and a 10% gain was defined as clinically important. 16 Besides the base-case scenario, we applied the utility values from a systematic review specifically focusing on breast cancer. 19 This comprehensive literature review reported utility values of 0.845, 0.703, and 0.648, for TWiST, TOX, and REL health states, respectively.
Threshold Utility Analyses (Sensitivity Analyses). To reflect the real situation that U TOX and U REL can vary independently of each other and over a range of values, Q-TWiST was calculated with U TOX and U REL ranging from a minimum of 0.0 (survival time in TOX and/or REL was not counted toward total Q-TWiST) to a maximum of 1.0 (survival time in TOX and/or REL was fully counted), assuming the utility of TWiST was fixed at 1.0. Thus, results were displayed across the range of utilities from 0.0 to 1.0 for TOX and REL in a panel graph. In the panel, we further provided diagonal bands of different shading to reflect the magnitude of relative Q-TWiST gain between nab-P and Pac. In addition, we presented estimates for 9 combinations of TOX and REL utility values (with utilities of 0.0, 0.5, or 1.0).
Statistical Analyses
Patient characteristics were summarized using descriptive statistics; c 2 tests were conducted for categorical variables, and the t test was used for continuous variables to compare nab-P and Pac treatment groups.
For each treatment group in the ITT population and 2Lþ subpopulation, progression-free survival (PFS), TOX, and OS were estimated using the KaplaneMeier method. The differences in time spent in each health state across treatment arms were tested using a bootstrapping approach. Within the base case, mean survival times were measured from study entry through month 30. SAS version 9.3 (SAS Institute Inc, Cary, NC) was used for all analyses in the study. All P values were 2-sided and P values of < .05 were considered statistically significant.
Results

Baseline Patient Characteristics
The baseline characteristics were generally similar between patients across treatment arms (nab-P vs. Pac) in the ITT population (n ¼ 454) and the 2Lþ subpopulation (n ¼ 268; Table 1 ). In general, study participants were younger than 65 years old and white, with an ECOG performance status of 1 at baseline. For cancer-specific profiles, the majority of study participants had > 3 metastatic lesions and had visceral metastases, including liver, lung, and abdominal metastases.
Restricted Mean Time in PFS, TOX, TWiST, and REL, and Mean OS Figure 2 shows the partitioning of survival time for each treatment group into the 3 health states (TWiST, TOX, and REL) in the ITT population and the 2Lþ subpopulation, respectively.
Restricted mean duration of each health state and differences between the 2 treatment arms are shown in Table 2 . In the ITT population, TWiST and PFS were significantly longer for patients receiving nab-P compared with Pac (þ1.6 months for TWiST and þ2.0 months for PFS). There was a nonsignificant difference in TOX, REL, and OS between nab-P and Pac (Table 2 ). In the 2Lþ subpopulation, TWiST, PFS, and OS were significantly longer for patients receiving nab-P (þ1.8 months for TWiST, þ2.1 months for PFS, and þ2.5 months for OS) compared with Pac (Table 2) .
Quality-Adjusted Time Without Symptoms of Disease Progression or Toxicity of Treatment in the ITT Population and 2Lþ Subpopulation
Quality-adjusted time without symptoms of disease progression or toxicity of treatment differences according to various combinations of U TOX and U REL in the ITT population and 2Lþ subpopulation are presented according to treatment arm in Table 3 .
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In the ITT population, when utility weights for the TOX and REL health states were set equal to 0.5 (base-case scenario), a nonsignificant 1.4-month difference in quality-adjusted survival between nab-P and Pac was observed (11.6 months [95% CI, 10.5-12.7] vs. 10.2 months [95% CI, 9.3-11.1]; Table 3 ). In the 2Lþ subpopulation, the base-case scenario led to a statistically significant 2.2-month difference in quality-adjusted survival favoring nab-P over Pac (10.5 months [95% CI, 9.2-11.8] vs. 8.4 months [95% CI, 7.4-9.3]; Table 3 ). The relative gain in Q-TWiST between nab-P and Pac was 8.8% in the ITT population and 17.1% in the 2Lþ subpopulation.
Sensitivity Analyses
The threshold sensitivity analyses for the ITT population and 2Lþ subpopulation are shown in Figure 3A and B, respectively. 16 In the ITT population, all utility combinations resulted in positive Q-TWiST treatment differences, ranging from 0.8 to 2.0 months, all in favor of nab-P over Pac, with this benefit statistically significant (P < .05) for certain pairs of utility weights (relatively larger U TOX and smaller U REL ; Figure 3A ). In the 2Lþ subpopulation, the benefit in Q-TWiST (difference in scores ranging from 1.8 to 2.5 months; percent relative improvement in Q-TWiST ranging from 14.0% to 19.5%) was statistically significant across all pairs of utility weights ( Figure 3B ).
In addition to the threshold utility analysis, we further explored the results using the specific utility values derived from a systematic literature review of publications focusing on breast cancer. 19 When utilities of TWiST, TOX, and REL were set to 0.845, 0.703, and 0.648, respectively, there was a statistically significant difference in Q-TWiST between nab-P versus Pac (2.0 months [95% CI, 0.4-3.6]) in the 2Lþ subpopulation. However, the difference was not significant between the 2 treatment arms in the ITT population.
Other subgroups were also considered in the sensitivity analyses. Statistically significant benefits were seen for patients receiving nab-P compared with Pac among the following subgroups: patients having > 3 metastatic lesions and patients having time from initial diagnosis to relapse of < 2 years at baseline (data not shown).
Discussion
In the present study, the quality-adjusted survival time was longer in patients receiving nab-P versus Pac in the 2Lþ subpopulation. The robustness of the quality-adjusted survival advantage of nab-P was further confirmed by sensitivity analyses in this population. Quality-adjusted survival time ranged from 1.8 to 2.5 months (with corresponding percentage of relative improvement in Q-TWiST ranging from 14.0% to 19.5%), depending on the utility assigned to each health state in the study. Regardless of the utility weights applied in the model, the quality-adjusted survival advantage of nab-P remained evident in this subpopulation, which confirmed the considering differences in Q-TWiST of ! 10% of OS as "clinically important" and ! 15% of OS as "clearly clinically important." Therefore, the 17.1% of OS relative gain in Q-TWiST between nab-P and Pac was statistically significant and clearly clinically important in the 2Lþ subpopulation. Benefits of longer OS might be affected by disease symptoms and AEs that contribute to the burden of disease and impair QOL. Patients who gained survival time might encounter increased drug toxicity, disease progression, or both. The Q-TWiST analysis provides an approach that allows the examination of OS, toxicity, and progression as a single metric. 20 The valuation of utility weights is a challenging issue in defining quality-adjusted survival because most clinical trials do not collect utility values prospectively. The sensitivity analysis overcomes the inherent uncertainty associated with derivation of utility weights in this analysis.
On the basis of a recent systematic literature review on Q-TWiST in oncology conducted by Solem et al, 17 only approximately 10% of breast cancer Q-TWiST publications (representing one-half of the published oncology Q-TWiST articles included in the review) reported a clinically important (! 10% of OS) improvement in Q-TWiST in the treatment arm (vs. control arm). This proportion is relatively low compared with that in Q-TWiST studies of other cancers (ie, approximately 35% reporting a clinically important improvement overall). 17 The findings of this analysis in the 2Lþ subpopulation showed a relative gain in Q-TWiST of 17.1% of OS, which is high compared with that in most of the previously published Q-TWiST studies in breast cancer. It is considered a clearly clinically important improvement on the basis of the criteria by Revicki et al. 16 This study has several limitations that should be considered. First, 1 set of utility values was assigned to the 2 treatment regimens despite that patient-derived utility values might be different between study treatments, even after adjusting for progression or toxicities. Although this limitation was not addressed, a threshold sensitivity analysis was conducted to examine the Q-TWiST difference across possible ranges of TOX and REL utility values, which allows assessment of the results at different TOX and REL utility combinations. Second, only toxicities reported as Grade ! 3 were considered in the TOX time. However, the severity of toxicity might change over time (eg, from Grade 3 to Grade 2, then back to Grade 3) and the actual timing of AE Grade changes might not have been precisely reported in the clinical trial. In addition, it is possible that AEs and progression occurred at the same time. The combination of having AEs while progressing could result in an even lower utility, which was not identified in the present study. Third, there are limitations to assigning relative utilities as opposed to directly eliciting QOL scores from patients. Specifically, some drug effects might not be reported in this study as AEs (eg, Grade < 3 AEs) but could still affect patient QOL. Finally, this quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis was performed using data from the phase III registration trial comparing nab-P to 3-weekly paclitaxel. The potential effect of a weekly versus 3-weekly paclitaxel regimen could not be assessed.
Conclusion
The results of this analysis showed that in patients with MBC who initiated the study drugs 2Lþ (the approved indication of nab-P), nab-P provided a statistically significant and clinical meaningful improvement compared with Pac, measured according to QTWiST. In the ITT population, patients treated with nab-P had similar Q-TWiST and PFS versus Pac. The actual magnitude of the clinical benefit associated with nab-P depends on the utility values an individual patient might assign to time with toxicity and time after disease progression. Further studies are needed to investigate the diversity of utility weights in patients treated with chemotherapy and with different sets of preferences.
Clinical Practice Points
The goal of breast cancer treatment is to prolong OS and PFS without a negative effect on QOL. Therefore, measurement of QOL and gauging the effect of treatment remains at the forefront of breast cancer research. nab-P has been approved by the European Medicines Agency and the United States Food and Drug Administration for the treatment of MBC in adult patients for whom first-line treatment for metastatic disease failed and for whom standard anthracycline-containing therapy is not indicated on the basis of the results of a phase III trial versus Pac. However, there is limited evidence on the effect of nab-P treatment on QOL in these patients, and no studies have compared the qualityadjusted survival between nab-P and Pac in patients with MBC. 
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This analysis was therefore undertaken to evaluate the benefit versus risk of nab-P versus Pac treatment on Q-TWiST, using data from the phase III registration trial.
The results of this analysis confirm the favorable risk-benefit profile of nab-P in the 2Lþ treatment setting (approved indication for nab-P) with a statistically significant and clinically meaningful improvement in quality-adjusted survival time versus Pac in patients with MBC. Additionally, the threshold analysis results could be used by clinicians to assess the risk/benefits of therapy, accounting for differences in toxicity and post-disease progression utilities.
